4 / 42
Eberhardt – J Thorac Oncol 2015
Pembrolizumab and long-term survivors 1
st
line
8
th
TNM IASLC Classification, 3-y OS M1c: ~8%
PD-L1 > 50% (N=138)
3yOS: 29.7%
3-y OS phase I KEYNOTE 001 Trial
Leighl– ASCO 2017
Pembrolizumab up to PD